OCA
OMGA

Octagon Capital Advisors’s Omega Therapeutics, Inc. Common Stock OMGA Stock Holding History

Octagon Capital Advisors’s Portfolio OMGA Stock Details OMGA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-176,470
Closed -$1.1M – 24
2022
Q1 		$1.1M Hold
176,470
– – 0.24% 22
2021
Q4 		$2M Sell
176,470
-193,809
-52% -$3.69M 0.39% 26
2021
Q3 		$6.98M Buy
+370,279
New +$7.1M 1.72% 17

Other funds holding OMGA

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Octagon Capital Advisors's OMGA Position: Q2 2022 in Review

Octagon Capital Advisors sold out of Omega Therapeutics, Inc. Common Stock (OMGA) in Q2 2022, closing a stake of 176,470 shares — an estimated $1.1M sold.

Octagon Capital Advisors first reported a position in OMGA in Q3 2021 and held it in 3 quarters. The position peaked at $6.98M in Q3 2021. 47 funds tracked by Wall St. Rank hold OMGA as of Q2 2022.

  • Octagon Capital Advisors reported no remaining Omega Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Octagon Capital Advisors sold 176,470 Omega Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $1.1M.
  • Octagon Capital Advisors first reported a position in Omega Therapeutics, Inc. Common Stock in Q3 2021 and held it in 3 quarters.
  • Octagon Capital Advisors's Omega Therapeutics, Inc. Common Stock position peaked at $6.98M in Q3 2021.
  • 47 funds tracked by Wall St. Rank held Omega Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Octagon Capital Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.